Ensiklopedia Dunia

Drospirenon
Data klinis
Pengucapan	Droe-SPY-re-nown
Nama dagang	Slynd
Nama lain	Dihidrospirenon; Dihidrospirorenon; 1,2-Dihidrospirorenon; MSp; SH-470; ZK-30595; LF-111; asam 17β-Hidroksi-6β,7β:15β,16β-dimetilena-3-okso-17α-pregn-4-ena-21-karboksilat, γ-lakton
AHFS/Drugs.com
License data	US DailyMed: Drospirenone;
Rute; pemberian	Oral
Kelas obat	Progestogen; Progestin; Antimineralocorticoid; Steroidal antiandrogen
Kode ATC	G03AC10 (WHO) ; G03AA12 G03FA17 (kombinasi dengan estrogen);
Status hukum
Status hukum	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; ℞ (Hanya resep);
Data farmakokinetika
Bioavailabilitas	66–85%
Pengikatan protein	95–97% (menjadi albumin)
Metabolisme	Hati (kebanyakan independen dari CYP450 (reduksi, sulfasi, dan pembelahan cincin lakton), beberapa kontribusi CYP3A4)
Metabolit	• Drospirenone acid; • 4,5-Dihydrodrospirenone 3-sulfate
Waktu paruh eliminasi	25–33 jam
Ekskresi	Urine, feses
Pengenal
	Nama IUPAC (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Heksadekahidro-10,13-dimetilspiro-[17H-disiklopropa[6,7:15,16]siklopenta[a]fenantrena-17,2'(5'H)-furan]-3,5'(2H)-diona;
Nomor CAS	67392-87-4 ;
PubChem CID	68873;
DrugBank	DB01395 ;
ChemSpider	62105 ;
UNII	N295J34A25;
KEGG	D03917 ;
ChEBI	CHEBI:50838 ;
ChEMBL	ChEMBL1509 ;
CompTox Dashboard (EPA)	DTXSID7046465 ;
ECHA InfoCard	100.060.599
Data sifat kimia dan fisik
Rumus	C24H30O3
Massa molar	366,50 g·mol−1
Model 3D (JSmol)	Gambar interaktif;
	SMILES O=C7O[C@@]6([C@@]3([C@H]([C@@H]2[C@@H]4[C@H](/C1=C/C(=O)CC[C@]1(C)[C@H]2CC3)C4)[C@@H]5C[C@@H]56)C)CC7;
	InChI InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 ; Key:METQSPRSQINEEU-HXCATZOESA-N ;
	(verify)

Drospirenon adalah obat progestin dan antiandrogen yang digunakan dalam pil kontrasepsi oral gabungan untuk mencegah kehamilan dan terapi hormon menopause.^[1]^[10] Obat ini tersedia baik sebagai sediaan tunggal maupun dalam kombinasi dengan etinilestradiol.^[10]^[4] Obat ini merupakan analog dari spironolakton.^[11] Obat ini diminum.^[1]^[4]

Efek samping yang umum termasuk jerawat, sakit kepala, nyeri payudara, peningkatan berat badan, dan perubahan menstruasi. Efek samping yang jarang terjadi mungkin termasuk kadar kalium tinggi dan pembekuan darah (bila dikonsumsi sebagai pil kombinasi estrogen-progestogen), antara lain.^[4]^[12] Drospirenon adalah progestin atau progestogen sintetis, dan karenanya merupakan agonis reseptor progesteron, yakni target biologis progestogen seperti progesteron. Obat ini memiliki aktivitas antimineralokortikoid dan antiandrogenik tambahan dan tidak memiliki aktivitas hormonal penting lainnya.^[1] Karena aktivitas antimineralokortikoidnya dan kurangnya aktivitas off-target yang tidak diinginkan, drospirenon dikatakan lebih mirip dengan progesteron bioidentik daripada progestin lainnya.^[13]^[14]

Drospirenon dipatenkan pada tahun 1976 dan diperkenalkan untuk penggunaan medis pada tahun 2000.^[15]^[16] Obat ini tersedia secara luas di seluruh dunia.^[10] Obat ini terkadang disebut sebagai "progestin generasi keempat".^[17]^[18] Obat ini tersedia sebagai obat generik.^[19]

Referensi

^ ^a ^b ^c ^d ^e ^f ^g Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1 (sup1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
^ "Lucinda (Lupin Australia Pty Limited)". Therapeutic Goods Administration (TGA). 14 January 2025. Diakses tanggal 20 January 2025.
^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Diakses tanggal 25 March 2024.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ Templat:DailyMed
^ ^a ^b ^c ^d Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226.
^ Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocrine Reviews. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
^ Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R (April 2004). "A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles". Contraception. 69 (4): 271–278. doi:10.1016/j.contraception.2003.11.003. PMID 15033400.
^ Bachmann G, Kopacz S (November 2009). "Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin". Patient Preference and Adherence. 3: 259–264. doi:10.2147/PPA.S3901. PMC 2778416. PMID 19936169.
^ Wiesinger H, Berse M, Klein S, Gschwend S, Höchel J, Zollmann FS, Schütt B (December 2015). "Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol". British Journal of Clinical Pharmacology. 80 (6): 1399–1410. doi:10.1111/bcp.12745. PMC 4693482. PMID 26271371.
^ ^a ^b ^c Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Drugs.com
^ Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception (dalam bahasa English). 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226. Pemeliharaan CS1: Bahasa yang tidak diketahui (link)
^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama pmid26598309
^ Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care (Review). 5 (Suppl 3): 17–24. doi:10.1080/14730782.2000.12288986. PMID 11246598. S2CID 35051390.
^ Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care (Review). 7 (Suppl 3): 19–26, discussion 42–3. doi:10.1080/14730782.2000.12288986. PMID 12659403.
^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Ravina2011
^ Alapi EM, Fischer J (2006). "Part III: Table of Selected Analogue Classes". Dalam Fischer J, Ganellin CR (ed.). Analogue-based Drug Discovery (dalam bahasa Inggris). John Wiley & Sons. hlm. 459. ISBN 978-3-527-60749-5.
^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama HatcherM.D.2007
^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama RossoZeichner2016
^ Generic Yasmin Availability via entryat Drugs.com

Bacaan lebih lanjut

Archer DF (February 2007). "Drospirenone and estradiol: a new option for the postmenopausal woman". Climacteric. 10 (Suppl 1): 3–10. doi:10.1080/13697130601114859. PMID 17364592. S2CID 9221524.
Archer DF (February 2007). "Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data". The Journal of Reproductive Medicine. 52 (2 Suppl): 159–164. PMID 17477110.
Archer DF (2007). "Drospirenone, a progestin with added value for hypertensive postmenopausal women". Menopause. 14 (3 Pt 1): 352–354. doi:10.1097/gme.0b013e31804d440b. PMID 17414576.
Batur P, Casey PM (February 2017). "Drospirenone Litigation: Does the Punishment Fit the Crime?". Journal of Women's Health. 26 (2): 99–102. doi:10.1089/jwh.2016.6092. PMID 27854556.
Bitzer J, Paoletti AM (2009). "Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials". Clinical Drug Investigation. 29 (2): 73–78. doi:10.2165/0044011-200929020-00001. PMID 19133702. S2CID 10356578.
Carranza-Lira S (2009). "Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review". Clinical Interventions in Aging. 4: 59–62. doi:10.2147/CIA.S4117. PMC 2685225. PMID 19503766.
Christiansen C (October 2005). "Effects of drospirenone/estrogen combinations on bone metabolism". Climacteric. 8 (Suppl 3): 35–41. doi:10.1080/13697130500330283. PMID 16203654. S2CID 42803561.
Dickerson V (November 2002). "Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone". The Journal of Reproductive Medicine. 47 (11 Suppl): 985–993. PMID 12497673.
Fenton C, Wellington K, Moen MD, Robinson DM (2007). "Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris". Drugs. 67 (12): 1749–1765. doi:10.2165/00003495-200767120-00007. PMID 17683173. S2CID 46976925.
Foidart JM (October 2005). "Added benefits of drospirenone for compliance". Climacteric. 8 (Suppl 3): 28–34. doi:10.1080/13697130500330309. PMID 16203653. S2CID 31883491.
Foidart JM, Faustmann T (December 2007). "Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen". Gynecological Endocrinology. 23 (12): 692–699. doi:10.1080/09513590701582323. PMID 18075844. S2CID 12572825.
Genazzani AR, Mannella P, Simoncini T (February 2007). "Drospirenone and its antialdosterone properties". Climacteric. 10 (Suppl 1): 11–18. doi:10.1080/13697130601114891. PMID 17364593. S2CID 24872884.
Han L, Jensen JT (October 2014). "Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive". Expert Opinion on Pharmacotherapy. 15 (14): 2071–2079. doi:10.1517/14656566.2014.949237. PMID 25186109. S2CID 25338932.
Heinemann LA, Dinger J (2004). "Safety of a new oral contraceptive containing drospirenone". Drug Safety. 27 (13): 1001–1018. doi:10.2165/00002018-200427130-00003. PMID 15471507. S2CID 1773936.
Idota N, Kobayashi M, Miyamori D, Kakiuchi Y, Ikegaya H (March 2015). "Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature". Legal Medicine. 17 (2): 109–115. doi:10.1016/j.legalmed.2014.10.001. PMID 25454533.
Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treatments in Endocrinology. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226.
Larivée N, Suissa S, Khosrow-Khavar F, Tagalakis V, Filion KB (September 2017). "Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies". BJOG. 124 (10): 1490–1499. doi:10.1111/1471-0528.14623. PMID 28276140.
Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A (2015). "Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review". The European Journal of Contraception & Reproductive Health Care. 20 (5): 329–343. doi:10.3109/13625187.2015.1050091. PMID 26007631. S2CID 41601833.
Li J, Ren J, Sun W (March 2017). "A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 210: 13–21. doi:10.1016/j.ejogrb.2016.11.013. PMID 27923166.
Machado RB, Pompei LD, Giribela AG, Giribela CG (January 2011). "Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits". Women's Health. 7 (1): 19–30. doi:10.2217/whe.10.84. PMID 21175386.
Mallareddy M, Hanes V, White WB (2007). "Drospirenone, a new progestogen, for postmenopausal women with hypertension". Drugs & Aging. 24 (6): 453–466. doi:10.2165/00002512-200724060-00002. PMID 17571911. S2CID 39236155.
Motivala A, Pitt B (2007). "Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?". Drugs. 67 (5): 647–655. doi:10.2165/00003495-200767050-00001. PMID 17385938. S2CID 22985078.
Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care. 7 (Suppl 3): 19–26, discussion 42–3. PMID 12659403.
Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care. 5 (Suppl 3): 17–24. doi:10.1080/14730782.2000.12288986. PMID 11246598. S2CID 35051390.
Oelkers W (March 2004). "Drospirenone, a progestogen with antimineralocorticoid properties: a short review". Molecular and Cellular Endocrinology. 217 (1–2): 255–261. doi:10.1016/j.mce.2003.10.030. PMID 15134826. S2CID 19936032.
Oelkers W (February 2002). "The renin-aldosterone system and drospirenone". Gynecological Endocrinology. 16 (1): 83–87. doi:10.1080/gye.16.1.83.87. PMID 11915587. S2CID 32410408.
Oelkers WH (October 2005). "Drospirenone in combination with estrogens: for contraception and hormone replacement therapy". Climacteric. 8 (Suppl 3): 19–27. doi:10.1080/13697130500330341. PMID 16203652. S2CID 42837148.
Palacios S, Foidart JM, Genazzani AR (November 2006). "Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism". Maturitas. 55 (4): 297–307. doi:10.1016/j.maturitas.2006.07.009. hdl:2268/9932. PMID 16949774.
Pérez-López FR (June 2008). "Clinical experiences with drospirenone: from reproductive to postmenopausal years". Maturitas. 60 (2): 78–91. doi:10.1016/j.maturitas.2008.03.009. PMID 18468818.
Rapkin AJ, Sorger SN, Winer SA (February 2008). "Drospirenone/ethinyl estradiol". Drugs of Today. 44 (2): 133–145. doi:10.1358/dot.2008.44.2.1191057. PMID 18389090. S2CID 32413831.
Rapkin AJ, Winer SA (May 2007). "Drospirenone: a novel progestin". Expert Opinion on Pharmacotherapy. 8 (7): 989–999. doi:10.1517/14656566.8.7.989. PMID 17472544. S2CID 6954183.
Rapkin RB, Creinin MD (October 2011). "The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium". Expert Opinion on Pharmacotherapy. 12 (15): 2403–2410. doi:10.1517/14656566.2011.610791. PMID 21877996. S2CID 40231903.
Rübig A (October 2003). "Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties". Climacteric. 6 (Suppl 3): 49–54. PMID 15018248.
Scheinfeld NS (2007). "Yaz (3 mg drospirenone/20 microg ethinyl estradiol)". Skinmed. 6 (6): 289. doi:10.1111/j.1540-9740.2007.07338.x. PMID 17975349.
Sehovic N, Smith KP (May 2010). "Risk of venous thromboembolism with drospirenone in combined oral contraceptive products". The Annals of Pharmacotherapy. 44 (5): 898–903. doi:10.1345/aph.1M649. PMID 20371756. S2CID 8248469.
Shulman LP (June 2006). "A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone". Journal of Women's Health. 15 (5): 584–590. doi:10.1089/jwh.2006.15.584. PMID 16796485.
Simoncini T, Genazzani AR (February 2010). "A review of the cardiovascular and breast actions of drospirenone in preclinical studies". Climacteric. 13 (1): 22–33. doi:10.3109/13697130903437375. PMID 19938948. S2CID 4306359.
Sitruk-Ware R (October 2005). "Pharmacology of different progestogens: the special case of drospirenone". Climacteric. 8 (Suppl 3): 4–12. doi:10.1080/13697130500330382. PMID 16203650. S2CID 24205704.
Thorneycroft IH (November 2002). "Evolution of progestins. Focus on the novel progestin drospirenone". The Journal of Reproductive Medicine. 47 (11 Suppl): 975–980. PMID 12497671.
Toni I, Neubert A, Botzenhardt S, Gratzki N, Rascher W (September 2013). "Venous thromboembolism in adolescents associated with drospirenone-containing oral contraceptives - two case reports". Klinische Padiatrie. 225 (5): 266–267. doi:10.1055/s-0033-1353169. PMID 23975850. S2CID 19085818.
White WB (February 2007). "Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension". Climacteric. 10 (Suppl 1): 25–31. doi:10.1080/13697130601114933. PMID 17364595. S2CID 9451771.
Whitehead M (March 2006). "Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data". The Journal of the British Menopause Society. 12 (Suppl 1): 4–7. doi:10.1258/136218006775992185. PMID 16513012. S2CID 38095916.
Wu CQ, Grandi SM, Filion KB, Abenhaim HA, Joseph L, Eisenberg MJ (June 2013). "Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review". BJOG. 120 (7): 801–810. doi:10.1111/1471-0528.12210. PMID 23530659. S2CID 206904730.
Zhao X, Zhang XF, Zhao Y, Lin X, Li NY, Paudel G, Wang QY, Zhang XW, Li XL, Yu J (September 2016). "Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis". Gynecological Endocrinology. 32 (9): 685–689. doi:10.1080/09513590.2016.1183629. PMID 27176003. S2CID 9116138.
"Drospirenone in HRT?". Drug and Therapeutics Bulletin. 47 (4): 41–44. April 2009. doi:10.1136/dtb.2009.03.0011. PMID 19357298. S2CID 1909717.

[Kuhl2005-1] ^ ^a ^b ^c ^d ^e ^f ^g Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1 (sup1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.

[2] "Lucinda (Lupin Australia Pty Limited)". Therapeutic Goods Administration (TGA). 14 January 2025. Diakses tanggal 20 January 2025.

[3] "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Diakses tanggal 25 March 2024.

[Slynd-Label-4] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ Templat:DailyMed

[Krattenmacher2000-5] Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception. 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226.

[pmid23238854-6] Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocrine Reviews. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.

[7] Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R (April 2004). "A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles". Contraception. 69 (4): 271–278. doi:10.1016/j.contraception.2003.11.003. PMID 15033400.

[Bachmann2009-8] Bachmann G, Kopacz S (November 2009). "Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin". Patient Preference and Adherence. 3: 259–264. doi:10.2147/PPA.S3901. PMC 2778416. PMID 19936169.

[WiesingerBerse2015-9] Wiesinger H, Berse M, Klein S, Gschwend S, Höchel J, Zollmann FS, Schütt B (December 2015). "Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol". British Journal of Clinical Pharmacology. 80 (6): 1399–1410. doi:10.1111/bcp.12745. PMC 4693482. PMID 26271371.

[Drugs.com-10] Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Drugs.com

[11] Krattenmacher R (July 2000). "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen". Contraception (dalam bahasa English). 62 (1): 29–38. doi:10.1016/S0010-7824(00)00133-5. PMID 11024226. Pemeliharaan CS1: Bahasa yang tidak diketahui (link)

[pmid26598309-12] Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama pmid26598309

[pmid11246598-13] Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care (Review). 5 (Suppl 3): 17–24. doi:10.1080/14730782.2000.12288986. PMID 11246598. S2CID 35051390.

[pmid12659403-14] Oelkers W (December 2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care (Review). 7 (Suppl 3): 19–26, discussion 42–3. doi:10.1080/14730782.2000.12288986. PMID 12659403.

[Ravina2011-15] Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Ravina2011

[Fis2006-16] Alapi EM, Fischer J (2006). "Part III: Table of Selected Analogue Classes". Dalam Fischer J, Ganellin CR (ed.). Analogue-based Drug Discovery (dalam bahasa Inggris). John Wiley & Sons. hlm. 459. ISBN 978-3-527-60749-5.

[HatcherM.D.2007-17] Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama HatcherM.D.2007

[RossoZeichner2016-18] Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama RossoZeichner2016

[Drugs.com-Generic-19] Generic Yasmin Availability via entryat Drugs.com

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

Ensiklopedia Dunia

Drospirenon

Referensi

Bacaan lebih lanjut

Beranda

Program Studi